Company: AGIO
Filing Date: 2025-10-30
Form Type: 10-Q
Source: 0001439222-25-000116
Chunk: 183

Company: AGIOS PHARMACEUTICALS, INC.
Filing Date: 2025-10-30
Form: 10-Q
Item: Part I, Item 8
Chunk 183
---
 at September 30, 2025477,006 $31.47 Stock-based compensation expense associated with these PSUs is recognized if the underlying performance condition is considered probable of achievement using our management’s best estimates.As of September 30, 2025, there was no unrecognized compensation expense related to PSUs with performance-based vesting criteria that are considered probable of achievement, and $15.0 million of total unrecognized compensation expense related to PSUs with performance-based vesting criteria that are considered not probable of achievement.2013 Employee Stock Purchase PlanIn June 2013, our Board of Directors adopted, and in July 2013 our stockholders approved, the 2013 Employee Stock Purchase Plan, or the 2013 ESPP. We issued and sold 133,283 and 102,805 shares of common stock during the nine months ended September 30, 2025 and 2024, respectively, under the 2013 ESPP. The 2013 ESPP provides participating employees with the opportunity to purchase up to an aggregate of 2,363,636 shares of our common stock. As of September 30, 2025, we had 1,449,951 shares of common stock available for future issuance under the 2013 ESPP.

15

Stock-based compensation expenseStock-based compensation expense by award type included within the condensed consolidated statements of operations is as follows:Three Months EndedSeptember 30,Nine Months EndedSeptember 30,(In thousands)2025202420252024Stock options$4,365 $4,579 $13,387 $13,011 Restricted stock units7,655 6,314 21,846 17,491 Performance-based stock units— — 2,188 750 Employee stock purchase plan357 252 1,007 692 Total stock-based compensation expense$12,377 $11,145 $38,428 $31,944 Expenses related to stock options and stock-based awards were allocated as follows in the condensed consolidated statements of operations:Three Months Ended September 30,Nine Months Ended September 30,(In thousands)2025202420252024Research and development expense$5,146 $4,391 $15,086 $12,626 Selling, general and administrative expense7,231 6,754 23,342 19,318 Total stock-based compensation expense$12,377 $11,145 $38